Your browser doesn't support javascript.
loading
The Clinical Course of Bowel Urgency Severity Among Patients with Inflammatory Bowel Disease-A Real-World Study.
Lewis, James D; Gibble, Theresa Hunter; Shan, Mingyang; Zhou, Xian; Naegeli, April N; Dawwas, Ghadeer K.
Affiliation
  • Lewis JD; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 7th Floor, Blockley Hall, 423 Guardian Drive, Philadelphia, PA, 19104-6021, USA. lewisjd@pennmedicine.upenn.edu.
  • Gibble TH; Eli Lilly and Company, Indianapolis, USA.
  • Shan M; Eli Lilly and Company, Indianapolis, USA.
  • Zhou X; Syneos Health, Morrisville, NC, USA.
  • Naegeli AN; Eli Lilly and Company, Indianapolis, USA.
  • Dawwas GK; Vanderbilt University Medical Center, Nashville, TN, USA.
Drugs Real World Outcomes ; 11(3): 403-412, 2024 Sep.
Article in En | MEDLINE | ID: mdl-38878264
ABSTRACT

BACKGROUND:

Bowel urgency is a highly burdensome symptom among patients with inflammatory bowel disease (IBD).

OBJECTIVES:

To assess changes in severity of bowel urgency and identify predictors of worsening or improvement among patients with Crohn's disease (CD) and ulcerative colitis (UC) at 6 months from their enrollment visit.

METHODS:

Data from patients in the Study of a Prospective Adult Research Cohort with IBD were analyzed. Enrolled patients with CD or UC with 6-month visits were included. Changes and predictors of bowel urgency severity over 6 months in patients with CD or UC were examined using two separate analyses (a) "worsening" versus "no change" excluding those with moderate-to-severe bowel urgency at enrollment, and (b) "improvement" versus "no change" excluding those with no bowel urgency at enrollment. The enrollment characteristics were compared within these groups.

RESULTS:

At baseline, in both CD and UC, use of biologics and/or immunomodulators at enrollment was similar across cohorts. Among patients with CD, 206 of 582 (35.4%) reported worsening, and 195 of 457 (42.7%) reported improvement in bowel urgency. Younger age (P = 0.013) and moderate-to-severe bowel urgency (P < 0.001) were associated with improvement. Moderate bowel urgency (P = 0.026) and bowel incontinence while awake (P = 0.022) were associated with worsening. Among patients with UC, 84 of 294 (28.6%) reported worsening, and 111 of 219 (50.7%) reported improvement in bowel urgency. Higher symptomatic disease severity (P = 0.011) and more severe bowel urgency (P < 0.001) were associated with improvement.

CONCLUSIONS:

Bowel urgency is an unpredictable and unstable symptom among patients with IBD. Over 50% of patients with CD or UC experienced either worsening or improvement at 6 months postenrollment.
WHAT IS KNOWN ABOUT BOWEL URGENCY IN INFLAMMATORY BOWEL DISEASE (IBD)? Around six to eight in every ten patients with inflammatory bowel disease suffer from bowel urgency, a sudden need to have bowel movement. Many patients with IBD perceive bowel urgency as a bothersome symptom impacting their everyday activities. WHY DID WE DO THIS STUDY? Despite the importance of bowel urgency, the changes in bowel urgency severity among the IBD-affected US population are yet to be fully known. We aimed to assess changes in severity of bowel urgency in patients with Crohn's disease (CD) or ulcerative colitis (UC) at 6 months. WHAT HAVE WE FOUND FROM THIS STUDY? Bowel urgency is a common and unpredictable symptom among patients with CD and UC. Over 50% of patients reported that the severity of bowel urgency has either worsened or improved at the 6 months postenrollment. While about 40­50% of IBD patients reported improvement, about 30% reported worsening, suggesting a lack of effective therapies to treat bowel urgency. FUTURE IMPLICATION There is a need for advanced therapies to resolve bowel urgency in patients with CD and UC.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Drugs Real World Outcomes Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Drugs Real World Outcomes Year: 2024 Document type: Article Affiliation country: Country of publication: